Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

Multistrategy hedge funds are bigger than ever. Some who have worked for the biggest brands are now advising others on how to ...

A Bloomberg analysis of the major hedge funds’ regulatory filings shows their passthrough fees have exploded in recent years.

Some of the biggest hedge fund managers have talked to Business Insider about what it takes to join their ranks. Here's what ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

Citadel offered a rare glimpse under the hood of its multistrategy funds during a lucrative period for the most profitable ...

Citadel's multistrategy flagship Wellington fund climbed 1.4% in January, following a 15.1% gain in 2024, according to the ...

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...

LONDON (Reuters) - Hedge funds started 2025 buoyed by choppier markets driven by uncertainty on new U.S. President Donald ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...